Tags Archives: cardiogenic shock

Perfusfind S.L.

Abstract Purpose: The outcomes of immunocompromised patients with cardiogenic shock treated with venoarterial extra‑corporeal membrane oxygenation (VA‑ECMO) are seldom documented, making ECMO candidacy decisions challeng‑ing. This study aims (1) to..

Perfusfind S.L.

Abstract Predictive survival models have been proposed to esti-mate survival rates in patients with refractory cardio-genic shock considered for veno-arterial extracorporeal membrane oxygenation (VA-ECMO) [1, 2]. Notably, the Survival after..

Perfusfind S.L.

Abstract Over the past decade, extracorporeal life support (ECLS) has gained increasing utilization in the management of refractory cardiogenic shock (CS) with a class IIaC recommendation according to the latest..

Perfusfind S.L.

Abstract Acute myocardial infarction-related cardiogenic shock (AMI-CS) carries a dismal prognosis. Short-term mortality is in the range of 40–50% [1]. Until recently, only treatment of the culprit lesion by percutaneous..

Perfusfind S.L.

Abstract Purpose of review  This article offers an overview of recent randomized controlled trials (RCTs) testing the efficacy of veno-arterial extracorporeal membrane oxygenation (VA ECMO) and microaxial flow pump (mAFP)..

Perfusfind S.L.

Abstract Aims This study evaluated how well serial pulse pressure (PP) and PP adjusted by the vasoactive inotropic score (VIS) predicted venoarterial extracorporeal membrane oxygenation (VA-ECMO) weaning success and clinical..

Perfusfind S.L.

Abstract Despite immediate coronary revascularization, mortality of patients experiencing infarct-related cardiogenic shock (AMICS) remains high [1]. Over the past decade, there has been a growing interest in the use of..

Perfusfind S.L.

Abstract Weaning and liberation from VA ECMO in cardiogenic shock patients comprises a complex process requiring a continuous trade off between multiple clinical parameters. In the absence of dedicated international..

Perfusfind S.L.

Abstract The objective was to investigate the outcomes of concomitant venoarterial extracorporeal membrane oxygenation (ECMO) and left ventricular unloading with Impella (ECPELLA) compared with ECMO alone to treat patients affected..

Perfusfind S.L.

Abstract The utilization of temporary mechanical circulatory support (tMCS) has increased significantly over the last 40 years for stabilization of salvageable patients; however, there has not been much improvement in..

Perfusfind S.L.

Abstract Background: The purpose of this investigation was to evaluate the impact of venoarterial extracorporeal membrane oxygenation (VA–ECMO) integrated hemoadsorption on the reversal of multiorgan and microcirculatory dysfunction, and early..

Perfusfind S.L.

Abstract Objective Although  (ECLS) has increasingly been used for the  of patients with  (CS), the outcomes of those successfully weaned from support remain poorly defined. Methods Of 510 venoarterial ECLS CS patients at..

Perfusfind S.L.

Abstract Background Reliable predictors of outcomes in venoarterial extracorporeal membrane oxygenation (VA-ECMO) therapy are limited. While elevated lactate levels over time have been linked to outcomes in cardiogenic shock (CS),..

Perfusfind S.L.

Abstract BACKGROUND The effects of temporary mechanical circulatory support with a microaxial flow pump on mortality among patients with ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock remains unclear...

Perfusfind S.L.

Abstract Purpose: Venoarterial extracorporeal membrane oxygenation (V-A ECMO) can be used to support severely ill patients with cardiogenic shock. While age is commonly used in patient selection, little is known..

Perfusfind S.L.

Abstract Cardiogenic shock (CS) is a critical clinical syndrome  characterized by inadequate tissue perfusion and oxygen  delivery resulting from severe heart dysfunction, leading  to multi-organ failure. Diagnostic criteria include hypoperfusion..

Perfusfind S.L.

Abstract Background The present article describes three cases of patients in cardiogenic shock (CS) with previous cardiac surgery that made them initially inoperable. Perioperative support with veno-arterial extracorporeal membrane oxygenation..

Perfusfind S.L.

Abstract Purpose: The outcomes of immunocompromised patients with cardiogenic shock treated with venoarterial extra‑corporeal membrane oxygenation (VA‑ECMO) are seldom documented, making ECMO candidacy decisions challeng‑ing. This study aims (1) to..

Perfusfind S.L.

Abstract Background This study examines the role of extracorporeal life support flow in the development of acute kidney injury in cardiogenic shock. Methods We performed a retrospective analysis of 465..

Perfusfind S.L.

Abstract Cardiogenic shock (CS) is a complex and life‐threatening condition characterized by a sudden and profound reduction in cardiac output, leading to inadequate tissue perfusion and oxygen delivery and organ..

Perfusfind S.L.

Abstract Background Venoarterial extracorporeal membrane oxygenation (ECMO) provides full hemodynamic support for patients with cardiogenic shock, but optimal timing of ECMO initiation remains uncertain. We sought to determine whether earlier..

Perfusfind S.L.

Abstract Peripheral venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly being used in patients suffering from refractory cardiogenic shock (CS). Although considered life-saving, peripheral VA-ECMO may also be responsible for intracardiac..

Perfusfind S.L.

Abstract Purpose: Cardiogenic shock is associated with high mortality. In refractory shock, it is unclear if mechanical circulatory support (MCS) devices improve survival. We conducted a network meta-analysis to determine..

Perfusfind S.L.

Abstract Background The present article describes three cases of patients in cardiogenic shock (CS) with previous cardiac surgery that made them initially inoperable. Perioperative support with veno-arterial extracorporeal membrane oxygenation..

Perfusfind S.L.

Abstract Cardiogenic shock is a complex and diverse pathological condition characterized by reduced myocardial contractility. The goal of treatment of cardiogenic shock is to improve abnormal hemodynamics and maintain adequate..

Perfusfind S.L.

Abstract Background Veno-arterial Extracorporeal Membrane Oxygenation (VA-ECMO) is a rescue treatment in refractory cardiogenic shock (CS) or refractory cardiac arrest (CA). Exposure to hyperoxemia is common during VA-ECMO, and its..

Perfusfind S.L.

Abstract OBJECTIVES:  This review aims to: 1) identify the key circuit and patient factors affecting systemic oxygenation, 2) summarize the literature reporting the association between hyperoxia and patient outcomes, and..

Perfusfind S.L.

Abstract The development of mechanical circulatory support (MCS) has been rapid, and its use worldwide in patients with cardiogenic shock is increasingly widespread. However, current statistical data and clinical research..

Perfusfind S.L.

Abstract Background: Cardiogenic shock is associated with high mortality. In refractory shock, it is unclear if mechanical circulatory support (MCS) devices improve survival. We conducted a systematic review and network meta-analysis..

Perfusfind S.L.

Abstract Background: Although extracorporeal membrane oxygenation (ECMO) is an integral part of a robust cardiogenic shock program, it is associated with high mortality. The optimal strategy for weaning from ECMO is..